![New Data Shows Stelara® (Ustekinumab) Maintained Clinical Response and Remission After Two Years of Treatment in Patients with Moderate to Severe Crohn's Disease - European Medical Journal New Data Shows Stelara® (Ustekinumab) Maintained Clinical Response and Remission After Two Years of Treatment in Patients with Moderate to Severe Crohn's Disease - European Medical Journal](https://www.emjreviews.com/wp-content/uploads/2017/06/PharmaMar-Announces-Encouraging...-940x566.jpg)
New Data Shows Stelara® (Ustekinumab) Maintained Clinical Response and Remission After Two Years of Treatment in Patients with Moderate to Severe Crohn's Disease - European Medical Journal
![Location is important: differentiation between ileal and colonic Crohn's disease | Nature Reviews Gastroenterology & Hepatology Location is important: differentiation between ileal and colonic Crohn's disease | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41575-021-00424-6/MediaObjects/41575_2021_424_Fig1_HTML.png)
Location is important: differentiation between ileal and colonic Crohn's disease | Nature Reviews Gastroenterology & Hepatology
![PDF) Transmural Healing Is Associated with Improved Long-term Outcomes of Patients with Crohn's Disease | Samuel Fernandes - Academia.edu PDF) Transmural Healing Is Associated with Improved Long-term Outcomes of Patients with Crohn's Disease | Samuel Fernandes - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/99815891/mini_magick20230314-1-rr4gzz.png?1678760523)
PDF) Transmural Healing Is Associated with Improved Long-term Outcomes of Patients with Crohn's Disease | Samuel Fernandes - Academia.edu
![Targeting Disease Progression in Crohn's Disease: Fighting an Unrelenting Enemy - European Medical Journal Targeting Disease Progression in Crohn's Disease: Fighting an Unrelenting Enemy - European Medical Journal](https://www.emjreviews.com/wp-content/uploads/2018/01/New-Website-Photographs-.8-940x564.jpg)
Targeting Disease Progression in Crohn's Disease: Fighting an Unrelenting Enemy - European Medical Journal
![Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG‐IBD study - Dragoni - 2023 - United European Gastroenterology Journal - Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG‐IBD study - Dragoni - 2023 - United European Gastroenterology Journal -](https://onlinelibrary.wiley.com/cms/asset/fa34ee68-f9f6-4d4f-ba5c-a3f91b1f5187/ueg212367-toc-0001-m.jpg)
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG‐IBD study - Dragoni - 2023 - United European Gastroenterology Journal -
![European Crohn's and Colitis Organisation returns to Vienna in 2018 - KONGRES – Europe Events and Meetings Industry Magazine European Crohn's and Colitis Organisation returns to Vienna in 2018 - KONGRES – Europe Events and Meetings Industry Magazine](https://kongres-magazine.eu/wp-content/uploads/2017/02/IMG_4737-800x600.jpg)